Holen Sie sich die Stockscreener-App
4.285
6.90%
-0.305
Schlusskurs vom Vortag:
$4.59
Offen:
$4.62
24-Stunden-Volumen:
302.87K
Relative Volume:
0.68
Marktkapitalisierung:
$203.33M
Einnahmen:
$114.70K
Nettoeinkommen (Verlust:
$-12.82M
KGV:
-1.6028
EPS:
-2.6735
Netto-Cashflow:
$-45.71M
1W Leistung:
+12.75%
1M Leistung:
+10.99%
6M Leistung:
+101.56%
1J Leistung:
+162.15%
1-Tages-Spanne:
$4.27
$4.7178
1-Wochen-Bereich:
$3.71
$5.15
52-Wochen-Spanne:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
4.271 | 218.52M | 114.70K | -12.82M | -45.71M | -2.6735 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.15 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.29 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.29 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.81 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
Chardan Capital Raises SAB Biotherapeutics Price Target to $14 - National Today
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00 - MarketBeat
H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution - Investing.com Canada
SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright - Defense World
SAB Biotherapeutics Announces Positive Phase 1 Results for SAB-142 Showing C-Peptide Preservation in Adult Type 1 Diabetes Patients - Minichart
SAB Biotherapeutics reports early C-peptide signals in phase 1 trial - Investing.com
SAB Biotherapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, and Strategic Outlook - Minichart
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - National Today
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright - MarketBeat
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data - TipRanks
SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes. - Bitget
SAB Bio reports Phase 1 SAB-142 data showing C-peptide preservation signals in adult T1D cohort - TradingView
SAB BIO Announces Additional Phase 1 Data for SAB-142 in - GlobeNewswire
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Investing News Network
SAB BIO backs diabetes therapy with $175M and 2027 trial goal - Stock Titan
SAB Biotherapeutics 10-K: Revenue $0, Net income $13.27M - TradingView
How rising interest rates impact SAB Biotherapeutics Inc. stockPortfolio Update Report & Consistent Profit Alerts - Naître et grandir
Aug Mood: Can SAB Biotherapeutics Inc ride the EV wavePortfolio Growth Summary & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Breakout Watch: Is SAB Biotherapeutics Inc a turnaround story2025 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Published on: 2026-03-07 05:05:40 - baoquankhu1.vn
Nasdaq Moves: Is SAB Biotherapeutics Inc a cyclical or defensive stockRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
SABS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewswire
Diabetes drug developer SAB Biotherapeutics at two Miami investor events - Stock Titan
SAB Biotherapeutics Pitches SAB-142 as Redosable Human ATG for Type 1 Diabetes at Oppenheimer Conf - MarketBeat
Geopolitics Watch: Should I buy SAB Biotherapeutics Inc stock nowJuly 2025 Update & Accurate Trade Setup Notifications - baoquankhu1.vn
SABS Should I Buy - Intellectia AI
Stock Report: What chart patterns are forming on SAB Biotherapeutics Inc Equity WarrantJuly 2025 Drop Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Entry Recap: What makes SAB Biotherapeutics Inc Equity Warrant stock attractive today2025 Price Targets & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
RTW INVESTMENTS, LP Acquires Significant Stake in SAB Biotherape - GuruFocus
RTW INVESTMENTS, LP Acquires Significant Stake in SAB Biotherapeutics Inc - GuruFocus
Is SAB Biotherapeutics Inc. a turnaround storyWeekly Profit Recap & Proven Capital Preservation Methods - mfd.ru
Will SAB Biotherapeutics Inc. stock maintain momentum in 2025Weekly Investment Report & Entry Point Confirmation Alerts - mfd.ru
Will SAB Biotherapeutics Inc. stock remain a Wall Street favoriteAnalyst Downgrade & Real-Time Market Trend Scan - mfd.ru
Stock Market Recap: Can YHNAR outperform in the next rallyOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
RTW discloses 3.2% SAB Biotherapeutics (SABS) position in 13G/A - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 24.7% - MarketBeat
SAB Biotherapeutics Spotlights SAB-142 Phase 2b Plan in Type 1 Diabetes at Guggenheim Summit 2026 - MarketBeat
Will SAB Biotherapeutics Inc. stock recover after earningsEarnings Miss & Short-Term Trading Opportunity Alerts - mfd.ru
What’s the profit margin of SAB Biotherapeutics Inc. Equity WarrantJuly 2025 Catalysts & Real-Time Buy Zone Alerts - mfd.ru
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 6.6%Here's What Happened - MarketBeat
Will SAB Biotherapeutics Inc. outperform small cap indexesJuly 2025 Summary & Accurate Intraday Trading Signals - mfd.ru
Aug Momentum: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
SAB Biotherapeutics, Inc. Management to Participate in February Investor Conferences - Quiver Quantitative
Biotech firm SAB Biotherapeutics joins fireside chats at 2 Feb. investor events - Stock Titan
Published on: 2026-01-31 17:26:58 - baoquankhu1.vn
Can SAB Biotherapeutics Inc. weather a recessionJuly 2025 Price Swings & Long-Term Safe Return Strategies - mfd.ru
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in SAB Biothe - GuruFocus
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement - MSN
Aug Patterns: Whats HTGCs historical return2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sab Biotherapeutics Inc-Aktie (SABS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):